<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310046</url>
  </required_header>
  <id_info>
    <org_study_id>TAVI PCI</org_study_id>
    <nct_id>NCT04310046</nct_id>
  </id_info>
  <brief_title>Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial</brief_title>
  <acronym>TAVI-PCI</acronym>
  <official_title>Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare, in patients with severe aortic stenosis&#xD;
      and concomitant coronary artery disease accepted for transcatheter aortic valve implantation&#xD;
      (TAVI) and percutaneous coronary intervention (PCI) by the multidisciplinary Heart Team, the&#xD;
      safety and efficacy of instantaneous wave-free ratio (iwFR)-guided complete revascularization&#xD;
      performed after (within 1-45 days) with iwFR-guided complete revascularization performed&#xD;
      before (within 1-45 days) TAVI using the Edwards SAPIEN Transcatheter Heart Valve®.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of coronary artery disease in patients with severe aortic stenosis is high.&#xD;
      About 30-60% of patients undergoing TAVI exhibit coexisting coronary artery disease. Optimal&#xD;
      timing of coronary revascularization in patients with severe aortic stenosis and concomitant&#xD;
      coronary artery disease undergoing TAVI is uncertain.&#xD;
&#xD;
      The goal of this investigator-initiated, randomized, multicenter, two-arm, open-label,&#xD;
      non-inferiority trial is to compare two treatment strategies that are currently performed in&#xD;
      clinical practice: PCI before TAVI versus PCI after TAVI in patients with severe aortic&#xD;
      stenosis and concomitant coronary artery disease.&#xD;
&#xD;
      In this trial, consecutive patients with severe aortic stenosis and concomitant coronary&#xD;
      artery disease accepted for TAVI and PCI by the Heart Team will be randomized in a 1:1 ratio&#xD;
      to the following strategies: iwFR-guided complete coronary revascularization before (within&#xD;
      1-45 days) or after (within 1-45 days) TAVI using the Edwards SAPIEN Transcatheter Heart&#xD;
      Valve®.&#xD;
&#xD;
      For both treatment groups, suitable lesions with iwFR≤0.89 or &gt;90% diameter stenosis on&#xD;
      coronary angiography in a coronary artery ≥2.5 mm in diameter are considered significant.&#xD;
&#xD;
      TAVI and PCI will be performed according to current guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">July 2028</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the number of participants experiencing the primary outcome measure</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome measure is a composite of:&#xD;
All-cause death&#xD;
Non-fatal myocardial infarction&#xD;
Ischemia-driven revascularization&#xD;
Rehospitalization (valve- or procedure-related including heart failure)&#xD;
Life-threatening/disabling or major bleeding (according to VARC-2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The primary outcome measure</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single components of the primary endpoint</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death and myocardial infarction</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death and myocardial infarction</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death, myocardial infarction and ischemia-driven revascularization</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death, myocardial infarction, ischemia-driven revascularization and rehospitalization</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural myocardial infarction (PCI)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural myocardial infarction (TAVI)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
    <description>Bleeding events are defined according to the Bleeding Academic Research Consortium (BARC) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom status and change from baseline in symptom status (Canadian Cardiovascular Society (CCS) and New York Hear Association (NYHA) classification)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (as assessed by the KCCQ and TASQ questionnaires)</measure>
    <time_frame>Admission (for second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
    <description>Kansas City Cardiomyopathy questionnaire (KCCQ) and the Toronto Aortic Stenosis Quality of Life questionnaire (TASQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quality of life (as assessed by the KCCQ and TASQ questionnaires)</measure>
    <time_frame>Admission (for second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
    <description>Kansas City Cardiomyopathy questionnaire (KCCQ) and the Toronto Aortic Stenosis Quality of Life questionnaire (TASQ)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Procedural success (PCI)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Device success (TAVI)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in resting and hyperemic indices for functional coronary lesion assessment from baseline to post TAVI</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Any revascularization</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>In-stent thrombosis</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New-onset atrial fibrillation</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New permanent pacemaker implantation</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aortic valve-related dysfunction requiring repeat procedure</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Amount of contrast medium (PCI)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fluoroscopy time (PCI)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Radiation exposure (dose area product, PCI)</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Conversion to open heart surgery</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Use of catecholamines during PCI</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Use of catecholamines during TAVI</measure>
    <time_frame>Discharge (hospitalization first and second procedure), 3 months, 1 year, 2 years and 5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">986</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>TAVI</condition>
  <condition>PCI</condition>
  <arm_group>
    <arm_group_label>PCI before TAVI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PCI is performed within 1-45 days before TAVI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI after TAVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCI is performed within 1-45 days after TAVI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI before TAVI</intervention_name>
    <description>TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with iwFR≤0.89 or &gt;90% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.</description>
    <arm_group_label>PCI before TAVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI after TAVI</intervention_name>
    <description>TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with iwFR≤0.89 or &gt;90% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.</description>
    <arm_group_label>PCI after TAVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥18 years with severe aortic stenosis and concomitant coronary artery disease&#xD;
             accepted for transfemoral TAVI with an Edwards SAPIEN Transcatheter Heart Valve™ and&#xD;
             PCI by a multidisciplinary Heart Team.&#xD;
&#xD;
          2. Severe aortic stenosis defined as aortic valve area (AVA) ≤1.0 cm2 and/or mean&#xD;
             pressure gradient ≥40 mmHg (echocardiography) and at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Dyspnea&#xD;
&#xD;
               2. Angina symptoms&#xD;
&#xD;
               3. Syncope&#xD;
&#xD;
               4. Decline in left ventricular ejection fraction &lt;50%, symptoms or fall in blood&#xD;
                  pressure on exercise testing, or presence of high-risk criteria (peak transaortic&#xD;
                  velocity &gt;5.5 m/s, severe valve calcification, peak transaortic velocity&#xD;
                  progression ≥0.3 m/s per year, or severe pulmonary hypertension with systolic&#xD;
                  pulmonary artery pressure &gt;60 mmHg) according to current guidelines.&#xD;
&#xD;
          3. At least one coronary artery lesion with 40-90% diameter stenosis and iwFR (or a&#xD;
             comparable resting index) ≤0.89 or with &gt;90% diameter stenosis on coronary angiogram&#xD;
             (by visual estimation) in a coronary artery ≥2.5 mm in diameter and Thrombolysis in&#xD;
             Myocardial Infarction (TIMI) flow grade III, deemed amenable to PCI within 45 days&#xD;
             before or after TAVI.&#xD;
&#xD;
          4. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. TAVI by transapical, subclavian, or transaortic access&#xD;
&#xD;
          2. Admission with acute myocardial infarction within 30 days before randomization&#xD;
&#xD;
          3. Elective coronary revascularization within 3 months before randomization&#xD;
&#xD;
          4. Previous coronary artery bypass grafting (CABG)&#xD;
&#xD;
          5. Syntax Score I ≥33&#xD;
&#xD;
          6. Any contraindications for dual antiplatelet therapy with aspirin and a P2Y12 inhibitor&#xD;
             (clopidogrel, ticagrelor or prasugrel), except for patients on oral anticoagulation&#xD;
&#xD;
          7. Planned open heart surgery&#xD;
&#xD;
          8. Known pregnancy at the time of inclusion&#xD;
&#xD;
          9. Life expectancy &lt;1 year due to other severe non-cardiac disease&#xD;
&#xD;
         10. Participation in another clinical study with an investigational product&#xD;
&#xD;
         11. Acute COVID-19 infection&#xD;
&#xD;
         12. Patient with previously treated aortic stenosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Kasel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara E. Stähli, MD, eMBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara E. Stähli, MD, eMBA</last_name>
    <phone>+41 44 255 11 11</phone>
    <email>Barbara.Staehli@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Kasel, MD</last_name>
    <email>markus.kasel@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zürich, Cardiology Department</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara E. Stähli, MD, eMBA</last_name>
      <email>barbara.staehli@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Valvular Disease</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Arteriosclerosis</keyword>
  <keyword>Arterial Occlusive Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

